Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

Blood. 2006 Dec 1;108(12):3951-2. doi: 10.1182/blood-2006-07-033571.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / adverse effects*
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Diphosphonates / administration & dosage
  • Diphosphonates / adverse effects*
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / adverse effects*
  • Jaw Diseases / chemically induced*
  • Jaw Diseases / etiology
  • Male
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy
  • Osteonecrosis / chemically induced*
  • Osteonecrosis / etiology
  • Retrospective Studies
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Thalidomide
  • Zoledronic Acid
  • Dexamethasone